Mohammed T. Abou-Saleh

400 PRINCIPLES AND PRACTICE OF GERIATRIC PSYCHIATRY3. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of majordepression in primary dementia. Arch Neurol 1990; 47: 209–14.4. Molchan SE, Lawlor BA, Hill JL et al. CSF monoamine metabolitesand somatostatin in Alzheimer’s disease and major depression. BiolPsychiat 1991; 29: 1110–18.5. Rodin G, Voshar K. Depression in the medically ill: an overview. AmJ Psychiat 1986; 143: 696–705.6. American Psychiatric Association Task Force on Laboratory Tests inPsychiatry. The dexamethasone suppression test: an overview of itscurrent status in psychiatry. Am J Psychiat 1987; 114: 1253–62.7. Fowler CJ, Tipton KF, MacKay AVP, Youdim MB. Human plateletmonoamine oxidase—useful enzyme in the study of psychiatricdisorders? Neuroscience 1982; 7: 1577–94.8. Loosen PT. The TRH stimulation test in psychiatric disorders: areview. In Nemeroff C, Loosen PT, eds, Handbook of ClinicalPsychoneuroendocrinology. New York: Guilford, 1987; 336–60.9. Cawley RH, Post F, Whitehead A. Barbiturate tolerance andpsychosocial functioning in elderly depressed patients. Psychol Med1973; 3: 39–52.10. Meyers BS, Kalayam B, Mei-Tal V. Late onset delusional depression:a distinct clinical entity? J Clin Psychiat 1984; 45: 347–9.11. Sweeney D, Nelson C, Bowers M et al. Delusional vs. non-delusionaldepression—neurochemical differences. Lancet 1978; ii: 100–101.12. Maes MH, De Rutyer M, Suy E. Prediction of subtype and severity ofdepression by means of dexamethasone suppression test, L-tryptophan: competing amino acid ratio, and MHPG flow. BiolPsychiat 1987; 22: 177–88.13. Edwards DJ, Spiker DG, Neil JF et al. MHPG excretion indepression. Psychiatry Res 1980; 2: 295–305.14. Meltzer HY, Hyong WC, Carroll BJ et al. Serum dopamine-bhydrozylaseactivity in the affective psychoses and schizophrenia.Arch Gen Psychiat 1976; 33: 585–91.15. Lykouras E, Markioanos M, Malliaras D, Stefanis C. Neurochemicalvariables in delusional depression. Am J Psychiat 1988; 145: 214–17.16. Veith RC, Raskind MA. The neurobiology of aging: does itpredispose to depression? Neurobiol Aging 1988; 9: 101–17.17. Kellner CH, Rubinow DR, Post RM. Cerebral ventricular size andcognitive impairment in depression. J Affect Disord 1986; 10: 2215–19.18. Kellner CH, Rubinow DR, Gold DW, Post RM. Relationship ofcortisol hypersection to brain CT scan alterations in depressedpatients. Psychiat Res 1983; 8: 191–7.19. Bridge TP, Soldo BJ, Phelps BH et al. Platelet monoamine oxidaseactivity: demographic characteristics contribute to enzyme activityvariability. J Gerontol 1985; 40: 23–8.20. Adolffson R, Gottfries CG, Oreland L et al. Increased activity ofbrain and platelet monoamine oxidase in dementia of Alzheimer type.Life Sci 1980; 27: 1029–34.21. Alexopoulos GS, Lieberman KW, Young RC. Platelet MAO activityin primary degenerative dementia. Am J Psychiat 1984; 141: 97–99.22. Davidson JRT, McLeod MN, Turnbull CD et al. Platelet monoamineoxidase activity and the classification of depression. Arch GenPsychiat 1980; 37: 771–3.23. White K, Shih J, Fong TL et al. Elevated platelet monoamine oxidaseactivity in patients with non-endogenous depression. Am J Psychiat1980; 137: 1258–9.24. Belmaker RH, Bracha HS, Ebstein RP. Platelet monoamine oxidasein affective illness and alcoholism. Schizophren Bull 1980; 6: 320–3.25. Ordway GA, Farley JT, Dilley GE et al. Quantitative distribution ofmonoamine oxidase A in brainstem monoamine nuclei is normal inmajor depression. Brain Res 1999; 847 (1): 71–9.26. Sastre M, Garcia-Sevilla, JA. Densities of 12-imidazoline receptors,a 2 -adrenoceptors and monoamine oxidase B in brains of suicidevictims. Neurochem Int 1997; 30 (1): 63–72.27. Alexopoulos GS, Lieberman KW, Young RC. Platelet MAO activityand age at onset of depression in elderly depressed women. Am JPsychiat 1984; 141: 1276–8.28. Schneider LS, Severson JA, Pollock V et al. Platelet monoamineoxidase activity in elderly depressed outpatients. Biol Psychiat 1986;21: 1360–64.29. Wahlund B, Saaf J, Wetterberg L. Clinical symptoms and plateletmonoamine oxidase in subgroups and different states of affectivedisorders. J Affect Disord 1995; 35: 75–87.30. Georgotas A, McCue RE, Friedman E et al. Relationship of plateletMAO activity to characteristics of major depressive illness. PsychiatRes 1986; 19: 247–56.31. Alexopoulos GS, Lieberman KW, Yound RC, Shamoian CA.Monoamines and monoamine oxidase in primary degenerativedementia. In Biology and Treatment of Dementia in the Elderly.Washington, DC: American Psychiatric Press, 1984, 59–71.32. Schneider LS, Severson JA, Sloane RB, Fredrickson E. Decreasedplatelet 3 H-imipramine binding in elderly outpatients with primarydepression compared to secondary depression. J Affect Disord 1988;15: 195–200.33. Qian Y, Lin S, Jiang S et al. Studies of the DXS7 polymorphism atthe MAO loci in unipolar depression. Am J Med Genet 1999; 88: 598–600.34. Franke L, Schewe HJ, Muller B et al. Serotonergic platelet variablesin unmedicated patients suffering from major depression and healthysubjects: relationship between 5-HT content and 5 HT-uptake. LifeSci 2000; 67: 301–5.35. Stanley M, Virgilio J, Geshon S. Tritiated imipramine binding sitesare decreased in frontal cortex of suicides. Science 1982; 216: 1337.36. Severson JA. 3 H-Imipramine binding in aged mouse brain: regulationby ions and serotonin. Neurobiol Aging 1986; 7: 83–7.37. Stanley M, Mann JJ. Serotonin-2 binding sites are increased in thefrontal cortex of suicide victims. Lancet 1983; i: 214–16.38. Zill P, Badberg F, de Jonge S et al. Serotonin transporter (5-HTT)gene polymorphism in psychogeriatric patients. Neurosci Lett 2000;284: 113–15.39. Menza MA, Palermo B, DiPaola R et al. Depression and anxiety inParkinson’s disease: possible effect of genetic variation in theserotonin transporter. J Geriat Psychiat Neurol 1999: 12: 49–52.40. Robinson RG, Chemerinski E, Jorge R. Pathophysiology ofsecondary depressions in the elderly. J Geriat Psychiat Neurol 1999:12: 128–36.41. Nobler MS, Mann JJ, Sackeim HA. Serotonin, cerebral blood flow,and cerebral metabolic rate in geriatric major depression and normalaging. Brain Res Brain Res Rev 1999; 30: 250–63.42. Sevincok L, Erol A. The prolactin response to buspirone inpoststroke depression: a preliminary report. J Affect Disord 2000;59: 169–73.43. Bligh-Glover W, Killi TN, Shapiro-Kulnane L et al. The serotonintransporter in the midbrain of suicide victims with major depression.Biol Psychiat 2000; 47: 1015–24.44. Jones JS, Stanley B, Mann JJ et al. CSF 5-HIAA and HVAconcentrations in elderly depressed patients who attempted suicide.Am J Psychiat 1990; 147: 1225–7.45. Langer SZ, Galzin AM, Poirier MF et al. Association of 3 H-imipramine 3 H-paroxetine binding with the 5-HT transporter in brainand platelets: relevance to studies in depression. J Receptor Res 1987;7: 499–521.46. Baron M, Barkai A, Gruen R et al. Platelet 3 H-imipramine binding inaffective disorders: trait vs. state characteristics. Am J Psychiat 1986;143: 711–17.47. Lewis DA, McChesney C. Tritiated imipramine binding distinguishesamong subtypes of depression. Arch Gen Psychiat 1985; 42: 485–8.48. Schneider LS, Fredrickson E, Severson J, Sloane RB. 3 H-imipraminebinding in depressed elderly: relationship to family history andclinical response. Psychiat Res 1986; 19: 257–66.49. Lawrence KM, Kanagasundaram M, Lowther S et al. [ 3 H]-imipramine binding in brain samples from depressed suicides andcontrols: 5-HT uptake sites compared with sites defined bydesmethylimipramine. J Affect Disord 1998; 47: 105–12.50. Georgotas A, Schweitzer J, McCue RE et al. Clinical and treatmenteffects on 3 H-clonidine and 3 H-imipramine binding in elderlydepressed patients. Life Sci 1987; 40: 2137–43.51. Nemeroff CB, Knight DL, Krishnan KRK et al. Marked reduction inthe number of platelet 3 H imipramine binding sites in geriatricdepression. Arch Gen Psychiat 1988; 45: 919–23.52. Langer SZ, Sechter D, Loo H et al. Electroconvulsive shock therapyand maximum binding of platelet tritiated imipramine binding indepression. Arch Gen Psychiat 1986; 43: 949–52.53. Schneider LS, Severson J, Chui HC et al. 3 H-imipramine binding andMAO activity in Alzheimer’s patients with agitation and delusions.Psychiat Res 1988; 25: 311–22.